Drug intelligence / Profile preview

RO5458640

Development stage: Unknown
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

RO5458640 is a humanized monoclonal antibody that targets the TNF-like weak inducer of apoptosis (TWEAK) ligand. It acts as an antagonist to TWEAK, which is also known as TNFSF12 or TNFRSF12A ligand. TWEAK binds to its receptor Fn14 and is involved in pathways regulating inflammation, proliferation, and apoptosis. By inhibiting TWEAK, RO5458640 aims to disrupt these signaling pathways that are implicated in tumor growth and progression. The drug was developed primarily for the treatment of advanced solid tumors and has been evaluated in phase 1 clinical trials for oncology indications[3][4][5][7].

Other names: anti-TWEAK monoclonal antibody

Targets

TNFSF12 (TWEAK)

Beyond the preview

Go deeper on RO5458640.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO5458640.

Explore the full profile